QVT Financial LP 4

What Happened QVT Financial LP (reported as "Director by Deputization") sold a total of 1,225,784 common shares of Roivant Sciences (ROIV) in a series of open‑market dispositions between Feb 11 and Feb 13, 2026. The sales ranged from $26.49 to $26.76 per share, generating aggregate proceeds of approximately $32.66 million. These were outright sales (S), not purchases or option exercises — typically routine disposition activity by an investment manager rather than an executive buy signal.

Key Details

• Transactions:
  • 2026-02-11: 425,000 shares @ $26.67 = $11,334,750
  • 2026-02-12: 150,000 shares @ $26.72 = $4,008,000
  • 2026-02-12: 275,000 shares @ $26.76 = $7,359,000
  • 2026-02-13: 150,784 shares @ $26.49 = $3,994,268
  • 2026-02-13: 225,000 shares @ $26.50 = $5,962,500
• Aggregate sold: 1,225,784 shares for ~$32,658,518.
• Shares owned after transaction: QVT (and related entities) may be deemed to beneficially own 25,161,237 common shares following these trades (per footnote F1).
• Footnote F2: QVT provides advisory services for related entities and disclaims beneficial ownership except to the extent of any pecuniary interest — institutional reporting, not necessarily direct control.
• Filing: Form 4 filed Feb 13, 2026 covering trades Feb 11–13; this filing date is within the SEC’s typical two‑business‑day reporting window.

Context

• This is institutional sell activity (an investment manager reporting sales on behalf of related accounts), not an executive insider purchase. Sales do not necessarily indicate negative company prospects — they can reflect portfolio rebalancing, liquidity needs, or other non‑company‑specific reasons.
• No derivatives, option exercises, gifts, or awards were reported in this Form 4 — only open‑market sales.